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Mutations to the gene encoding superoxide dismutase-1 (SOD1) were the first genetic ele-
ments discovered that cause motor neuron disease (MND). These mutations result in
compromised SOD1 dimer stability, with one of the severest and most common mutations
Ala4Val (A4V) displaying a propensity to monomerise and aggregate leading to neuronal
death. We show that the clinically used ebselen and related analogues promote thermal
stability of A4V SOD1 when binding to Cys111 only. We have developed a A4V SOD1 dif-
ferential scanning fluorescence-based assay on a C6S mutation background that is effective
in assessing suitability of compounds. Crystallographic data show that the selenium atom of
these compounds binds covalently to A4V SOD1 at Cys111 at the dimer interface, resulting in
stabilisation. This together with chemical amenability for hit expansion of ebselen and its on-
target SOD1 pharmacological chaperone activity holds remarkable promise for structure-
based therapeutics for MND using ebselen as a template.
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Amyotrophic lateral sclerosis (ALS), also referred to asmotor neuron disease (MND) and Lou Gehrig’s disease, ischaracterised by progressive degeneration of motor neu-
rons in the cerebral cortex and spinal cord. ALS patients typically
present with focal muscular weakness and progress to paralysis of
the diaphragm, which leads to respiratory failure and death
usually within 5 years of the onset of symptoms1. Although
approximately 90% of ALS cases are sporadic (sALS), the
remaining 10% of cases arise from inheritance of mutated genes
(familial type ALS; fALS), which are generally the cause of early
onset ALS1,2. The gene encoding Cu, Zn superoxide dismutase
(SOD1) was the first gene to be discovered as an ALS-linked
genetic factor in 19933. An alanine-to-valine mutation at amino
acid position 4 within the SOD1 protein (A4V), accounting for
50% of SOD1-related gene mutations in the US, causes a rapid
and aggressive form of fALS, thereby reducing survival time to
less than 2 years4.
SOD1 is a homodimeric copper-containing and zinc-
containing enzyme, serving as one of the cellular protective
mechanisms against reactive oxygen species5. However, SOD1-
fALS does not result from a malfunction in its enzymatic dis-
mutase activity. Instead, an increase in the aggregation propensity
of mutant SOD1 is thought to lead to disruption of physiological
homoeostasis, and has been considered a gain of function that
leads to fALS6. Previous studies suggested that SOD1 dimer
destabilisation and dissociation are critical for aggregation7–10. As
proof of principle, insertion of an inter-subunit disulphide linkage
by genetic modification inhibited SOD1 aggregation8, and several
small molecules have been shown to replicate this effect11–13.
With regard to its location at the solvent-accessible dimer inter-
face and its nucleophilicity, Cys111 has been a particular focus of
drug binding studies. This residue was demonstrated to be the site
of maleimide-derived compound binding in G93A and G85R
SOD1 which promoted thermostability11. Binding of cisplatin to
Cys111 also increases thermal stability, inhibits oligomerisation
and solubilises oligomers of wild-type metal free (apo) SOD112.
However, both compounds hinder the maturation of SOD1 by
preventing complex formation between SOD1 and its copper
chaperone (hCCS)14.
Ebselen is an organoselenium compound with activity similar to
glutathione peroxidase15. Several lines of evidence have demon-
strated the neuroprotective effects of ebselen, possibly via its anti-
oxidant properties16–18. The ability of ebselen to reduce mito-
chondrial cellular toxicity generated by mutant SOD1 indicates this
compound could play an important role in mitigating fALS19. We
recently demonstrated crystallographically that ebselen binds SOD1
at Cys111 and leads to an increase in dimer affinity of wild-type and
several SOD1 mutants without disruption of SOD1-hCCS com-
plex13. We also showed that ebselen promotes formation of the
Cys57-Cys146 disulphide bond of G93A and A4V SOD1 in human
cells13. Here we introduce an innovative derivative series of ebselen
and ebsulphur, a sulphur analogue of ebselen, that have been
designed to improve pharmacological effects. To evaluate the per-
formance of potential lead compounds, a differential scanning
fluorescence (DSF) assay using C6S background SOD1 has been
developed creating an effective medium-throughput screen report-
ing on binding at Cys111. Ebselen-based compounds, especially
with molecular weights below 400 Dalton, and some ebsulphur
derivatives promote thermal stability of A4V SOD1 in this DSF
assay. Moreover, we demonstrate that ebselen and a number of its
analogues form a covalent bond with Cys111 of A4V SOD1 using
x-ray crystallography. The combination of DSF assays on C6S
background SOD1 and co-crystallographic structures of com-
pounds with A4V SOD1 provide clear evidence of SOD1 thermal
stabilisation and offer opportunities for rational design for the next
generation of lead compounds.
Results
Synthesis of ebselen and ebsulphur analogues. In terms of
rationale for the analogues prepared, compound 1 was designed
to potentially enhance the cysteine reactivity of the ebselen core.
Compound 2 was designed to enhance aqueous stability of 1 by
incorporation of a basic benzyl morpholine ring system; Com-
pounds 3, 4 and 5 are simple benzyl analogues which have
greater flexibility than the parent drug substituted with electron
donating (−OMe) and with electron withdrawing (−Cl) groups.
Compounds 6 and 7 are biaryl analogues designed to enhance the
potential membrane permeability/penetration with 8–10 further
modified to incorporate protonatable nitrogens as more aqueous
soluble versions of 6 and 7. Also included in our analysis was a
series of ebsulphur (11) analogues (12, 13, 16–20) including
unreactive amide analogue (14) and phthalimide (15) as controls
to monitor the importance of a cysteine reactive warhead.
Figure 1 contains key data for the series (ClogP, ClogD, MW,
TPSA) along with data generated by the Pfizer central nervous
system multiparameter optimisation (CNS MPO) algorithm with
CNS MPO desirability scores20. The MPO scores for compounds
in Fig. 1 range from 2.6 to 6.0; compounds with a score of 4.0 or
higher are deemed to be more desirable and are predicted to be
more likely to reach their CNS drug target compared to
compounds with scores of 3.9 or less. The Pfizer CNS MPO
tool has helped increase the percentage of compounds nominated
for clinical development that exhibit alignment of ADME
attributes, cross the blood-brain barrier, and result in lower-risk
drug safety (low ClogP and high TPSA chemical space). As can be
seen from this data the ebselen analogues 1–5 have excellent
properties with 11, 12, 19 and 20 possessing the best all round
properties form the ebsulphur series.
Compounds that promote thermal stability of A4V SOD1.
There are two free cysteines in mature human SOD1. Cys111 is
located at the solvent accessible dimer interface and Cys6 is
located in β-strand 1 with side-chain projecting into the β-barrel
with limited access to solvent in the folded conformation. How-
ever, our DSF study on wild-type and A4V SOD1 showed a
biphasic melting curve or decreases in the melting temperature
when the proteins were incubated with ebselen overnight and the
excess ligands were removed by dialysis (Fig. 2a). The same
results were obtained from the wild-type and A4V SOD1 incu-
bated with compounds 1, 2, 6 and ebsulphur (Fig. 2a–d, and
Table 1). This might be because some of the compounds bind not
only at Cys111 but also interact with Cys6 in vitro as we
demonstrate in Supplementary Fig. 1 that C111S SOD1 with
ebselen shows the biphasic melting curve with the first melting
temperature (Tm) decreased 10 °C from the control. We thus
created a C6S mutant for the wild type and A4V mutant
removing the possibility of some proportion of the compound
binding to Cys6. DSF studies were performed on the C6S back-
ground for both wild-type and A4V SOD1 (WTC6S and A4VC6S).
The shifts in Tm of the proteins conjugated with ebselen-based
and ebsulphur-based derivatives are presented in Table 1. The
results show that most of the ebselen-based compounds increase
the Tm of WTC6S and A4VC6S notably except compounds 6 and
7, which decreased the Tm (Fig. 2e, f). A4VC6S bound to the lower
molecular mass compounds (ebselen, and compounds 1–5)
exhibits 4–8 °C increase in Tm, while the protein bound to the
larger hydrophobic compounds (compounds 8, 9 and 10) shows a
modest increase between 1–4 °C in Tm. The same trend was also
observed in WTC6S, albeit less pronounced as this pseudo-WT
protein is highly stable. We note that the increase in Tm by
ebselen, compounds 1 and 2 could not be observed in the wild-
type and A4V SOD1 without C6S mutation.
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Along with ebselen derivatives, we also investigated the effect
of ebsulphur and its analogues on the thermal stability of SOD1
(Fig. 2c, d, g, h). Despite ebsulphur-based compounds having
similar chemical structures to ebselen-based compounds, the
stability increases of both the WTC6S and A4VC6S are not
attained, with only compounds 12, 19 and 20, which contain
additional amide or ester linkers, showing a stabilising effect. We
also used 4-acetamido-4’-maleimidylstilbene-2,2’-disulfonic acid
(AMS) to observe modification of the free cysteines in A4VC6S
SOD1 monitored by denaturing SDS-PAGE separation. The
result shows that A4VC6S-ebsulphur migrates to the same level as
the control indicating Cys111 is not protected by reaction with
ebsulphur. Conversely, A4VC6S-ebselen shows a strong band
equivalent to disulphide reduced and unmodified SOD1 thus
indicating Cys111 is extensively protected by ebselen binding
(Supplementary Fig. 2). These observations are consistent with
the greater degree of reactivity of the ebselen core compared to
the ebsulphur based core.
Ebselen and its analogues covalently bind to A4V SOD1 at
Cys111. We recently described atomic-resolution crystal
structures of ebselen and ebsulphur bound to the Cys111 of wild-
type SOD1 and showed that the compounds restored the mutant
SOD1 post-translational modification pathway by promoting the
formation of the intra-subunit disulphide bond and increasing
dimer affinity13. Previously A4V has been crystallised in P212121
and P21 space groups that have provided insight into the desta-
bilisation of the A4V dimer20,21 but in contrast to other mutants,
no compound has ever been seen in A4V. In this study, we
successfully co-crystallised A4V SOD1 on wild-type background
(no C6S mutation) with various compounds in C2 space group
and provide direct visualisation of the binding of ebselen, com-
pounds 1, 4 and 6 at Cys111. Crystallographic data collection and
refinement statistics are presented in Table 2. The covalent bond
distances between the selenium atom of each compound and
sulphur atom of cysteine vary from 2.00–2.40 Å which can be due
to partial bond breakage during x-ray data collection. The elec-
tron density of the ligand in many Cys111 binding sites is clearly
visible except for some parts of the phenyl rings of ebselen,
pyridine rings of compound 1, chlorobenzyl ring of compound 4,
and the linker of compound 6 (Fig. 3). The absence of electron
density is probably due to the flexibility of these parts of the
ligands when exposed to solvent. Zn is in full occupancy in the Zn
Fig. 1 Calculated physicochemical properties of series including CNS multiparameter optimisation score. The values are colour coded according to
Wager51,52. Green; the values fall in more desirable range, red: the values fall in less desirable range, yellow: the values fall in-between the ranges. ClogP:
calculated logarithm of partition coefficient of a compound between n-octanol and water, ClogD: calculated logarithm of distribution coefficient of a
compound between n-octanol and water at pH 7.4, MW: molecular weight, tPSA: topological polar surface area, CNS MPO: central nervous system
multiparameter optimisation.
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binding site (Supplementary Fig. 3a). No electron density for the
compounds is seen around Cys6 (Supplementary Fig. 3b), the
other free cysteine in SOD1, which might be due to slightly
limited space and/or relatively weaker binding at Cys6. The dis-
ulphide bonds connecting Cys57 and Cys146 are intact (Sup-
plementary Fig. 3c). This means electrophilic reaction of our
selenium-containing compounds is preferable with Cys111 rather
than other cysteines in crystalline state.
The binding poses of ebselen, compounds 1 and 6 observed in
A4V SOD1 structures are similar in that the seleno-head group
covalently binds at Cys111 and the aromatic tail extends into the
surrounding solvent beyond the dimer groove (Fig. 3b, c, e). The
structure of A4V-compound 4 shows a different binding pose,
although the chemical structure is quite similar to ebselen with
only an additional methylene linker. The seleno-head group of
compound 4 is almost perpendicular to that of other compounds
and the chlorobenzyl group extends along the dimer groove,
filling the gap between N-termini and C-termini (Fig. 3d, f).
Although the covalent bond is the main interaction connecting
the ligand and the protein, two ligands facing each other at the
dimer interface are primarily linked by π-π stacking at aromatic
rings (Fig. 4). This stacking interaction might play an important
role in stabilising the dimer. Apart from the selenylsulphide bond,
all structures show additional interactions between the ligands
and the residues neighbouring Cys111, suggesting an asymme-
trical binding of the compounds to the protein (Fig. 4). Water-
bridging hydrogen bonds were observed in A4V-ebselen and
A4V-compound 1 structures, indirectly connecting carbonyl
group or aromatic ring of the ligands with Gly108 backbone or
Asp109 side chain (Fig. 4a, b). The phenyl ring of ebselen also
links with the peptide backbone of Gly108 and Asp109 through
an amide-π interaction, which is also observed in our previous
crystal structure of wild-type SOD1 conjugated with ebselen13.
The A4V-compound 1 structure shows an additional hydrogen
bond between the nitrogen atom of the pyridine ring and Gly108
backbone (Fig. 4b). The chlorobenzyl ring of compound 4 locates
near Thr2 and interacts with Ile151 through a hydrophobic σ-π
interaction, strengthening the binding of the compound by filling
Fig. 2 DSF screening of the small molecules bound to SOD1. Normalised melting curves of the wild-type (WT) and A4V SOD1 with and without (a, b)
ebselen derivatives and (c, d) ebsulphur. Normalised melting curves of WTC6S and A4VC6S with and without ebselen derivatives (e, f) and ebsulphur
derivatives (g, h). Each graph is an average of 3 independent experiments. Black dashed lines show the Tm (°C) of the control proteins: (a and c) WT SOD1;
72.4 °C, (b and d) A4V SOD1; 59.2 °C, (e and g) WTC6S SOD1; 70.7 °C, and (f and h) A4VC6S SOD1; 58.6 °C.
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the gap between N-termini and C-termini (Fig. 4c). In addition,
the phenyl ring of compound 6 interacts with Asp109 side-chain
oxygen atom through an anion-π interaction (Fig. 3d). Binding of
the ligands to A4V SOD1 does not seem to affect hydrogen
bonding and hydrophobic interactions between two monomers of
the dimer (Supplementary Table 1) or the distances between
residues at the dimer interface except the distances between loop
VI when comparing to the C2 A4V SOD1 structure (Supple-
mentary Table 2).
Monomer-monomer reorientation of ligand-conjugated A4V
SOD1. The A4V SOD1 substitution is known to change the
monomer-monomer orientation within a SOD1 dimer20. To
exclude the effect of differences imposed by crystal packing, the
crystal structure of A4V SOD1 in C2 form was used to compare
monomer-monomer orientation. The superposed structures of all
C2 forms show high similarity with the range of root-mean-
square deviation (RMSD) indicated in Fig. 5 and Table 3. The
major difference is in loop VI, residues 109–114, which is more
open in the compound-bound A4V structures (Fig. 5, box) with
some variations among structures and an asymmetry of this loop
between two monomers. The result suggests that loop VI is
slightly displaced upon ligand binding.
The orientation of two monomers of ligand-conjugated A4V
SOD1 was evaluated by superposition of monomer A of all
dimers in the asymmetric unit of each structure with the wild-
type SOD1 structure (Supplementary Fig. 4). The changes in
RMSD, angle of rotation, and displacement of monomer B were
then observed. Six dimers in the asymmetric unit (ASU) of the
P21 A4V structure (PDB code 1UXM) were also compared with
the wild-type SOD1 structure as a reference. The movement is
complex, with a combination of rotation and displacement
(Supplementary Fig. 4a). The comparison reveals that the changes
in the orientation of two monomers of ligand-conjugated A4V
SOD1 and C2 A4V structures are mostly within the range of
those found in P21 A4V SOD1 crystal structures (Supplementary
Fig. 4b), although the structures of A4V-compound 6 appear to
Table 1 ΔTm of the proteins conjugated with ebselen-based
and ebsulphur-based derivatives.
Compounds ΔTm (°C)
WT A4V WTC6S A4VC6S
Ebselen −10.5* −3.1 5.6 8.8
Cpd 1 1.0 −1.7 3.3 4.5
Cpd 2 −0.1 −0.4 3.1 4.0
Cpd 3 – – 5.4 8.8
Cpd 4 – – 3.7 6.7
Cpd 5 – – 4.8 8.7
Cpd 6 −9.9* −4.7 −6.6* −2.6
Cpd 7 – – −0.6 −3.4
Cpd 8 – – 3.0 3.9
Cpd 9 – – 1.7 1.3
Cpd 10 – – 3.4 3.9
Ebsulphur −0.3 −0.1 0.6 2.4
Cpd 12 – – 2.8 3.8
Cpd 13 – – 1.4 0.5
Cpd 14 – – 0.2 −1.5
Cpd 15 – – 0.5 −1.5
Cpd 16 – – 0.8 1.5
Cpd 17 – – 0.5 1.2
Cpd 18 – – 0.6 2.0
Cpd 19 – – 3.1 3.3
Cpd 20 – – 2.7 4.9
*ΔTm of the control and the first Tm of the biphasic curve derived by calculating the peak of the
first derivative of the raw data.
The figures are means of 3 independent experiments.
Table 2 Crystallographic data collection and refinement statistics.
A4V (C2) A4V-ebselen A4V-cpd 1 A4V-cpd 4 A4V-cpd 6
Data collection
Space group C2 C2 C2 C2 C2
Cell dimensions
a, b, c (Å) 112.60, 195.96, 75.68 112.31, 195.24, 75.35 112.51, 194.66, 75.17 113.53, 194.67, 146.52 112.66, 195.55, 76.34
α, β, γ (°) 90.00, 97.10, 90.00 90.00, 97.85, 90.00 90.00, 96.97, 90.00 90.00, 93.44, 90.00 90.00, 98.08, 90.00
Resolution (Å)a 97.98–1.65 (1.68–1.65) 47.85–2.25 (2.3–2.25) 97.33–1.97 (2.00–1.97) 58.47–2.80 (2.86–2.80) 97.77–2.77 (2.88–2.77)
Rmergea 6.66 (100.46) 8.4 (46.0) 7.1 (36.6) 17.4 (62.9) 15.5 (59.3)
I/σIa 11.4 (1.19) 10.3 (1.9) 6.7 (1.6) 3.7 (1.3) 4.7 (1.9)
CC1/2 (%)a 0.998 (0.465) 0.996 (0.639) 0.993 (0.776) 0.965 (0.538) 0.972 (0.674)
Completeness (%)a 99.6 (99.5) 97.3 (97.7) 99.2 (95.5) 99.7 (99.7) 100.0 (100.0)
Redundancya 3.4 (3.5) 3.5 (2.8) 2.9 (2.0) 3.1 (3.0) 3.3 (3.4)
Refinement
No. reflections 183807 70706 105982 73673 138246
Rwork/Rfree 16.89/19.61 18.59/22.26 18.28/22.61 21.32/24.11 21.18/22.89
No. atoms
Protein 6,893 6,688 6,869 13,385 6,683
Ligand/ion 95/6 169/6 318/18 306/12 308/22
Water 1375 812 1015 230 240
B-factors
Protein 23.24 18.59 32.15 31.82 48.22
Ligand/ion 37.36/17.77 28.62/15.20 46.0/29.38 85.56/23.72 61.99/31.21
Water 40.96 39.89 41.58 18.21 28.64
R.M.S. deviations
Bond lengths (Å) 0.013 0.008 0.008 0.008 0.005
Bond angles (°) 1.780 1.476 1.451 1.353 1.295
PDB code 6SPA 6SPH 6SPJ 6SPI 6SPK
aValues in parenthesis denote the highest resolution shell. The data of each structure was collected from one single crystal.
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shift away more than other ligand-bound A4V structures and
some dimers of A4V-compound 4 structure moves towards the
wild-type SOD1 structure, marginally further than A4V SOD1
without ligand. We note there is a structural variability across
A4V SOD1 structures which is not eliminated by crystallisation
and whether the subtle changes in the compound-bound A4V
SOD1 structures are related to the dimer stability requires further
investigation.
Discussion
ALS is a result of complex aetiologies, although clinical manifes-
tations of familial and sporadic types are similar. Both types of ALS
share a common feature, which is cytosolic protein aggregations
including SOD11. The A4V substitution is one of the most severe
SOD1 mutations and causes destabilisation and aggregation in fALS
individuals. While the mechanism of dimer destabilisation and the
increased propensity to aggregate remain elusive, several structural
and molecular dynamics studies have demonstrated that the A4V
mutation causes structural changes in neighbouring residues close
to the dimer interface, which potentially perturb overall dimer
stability even though the interface interactions are generally con-
served in the crystal structure20,22–24. The network of contact
interactions between the dimer interface and Zn binding loop is also
affected by A4V mutation. The disorder of the Zn-loop impairs the
Zn binding ability of SOD1 which together with the instability of
electrostatic loop, in turn, could alter the dimer interface23–25. As a
consequence of dimer destabilisation, dissociation of the dimer was
shown to cause exposure of the hydrophobic surface of each
monomer, resulting in protein aggregation7,26. Therefore, stabili-
sation of dimeric A4V SOD1 could be a potent strategy for the
development of ALS therapeutics.
Cys111 located at the edge of the dimer interface and exposed to
the surrounding environment serves as a double-edged sword. The
exposure of the thiol group of cysteine makes it prone to oxidative
damage by physiological oxidants such as oxidised glutathione or
thioredoxin27,28. This cysteine residue also plays a critical role in the
formation of incorrect inter-subunit disulphide bonds, leading to
toxic high molecular weight oligomers29,30, since substitution of
Cys111 with serine in SOD1 mutants, including A4V, and deme-
tallated wild-type SOD1 could mitigate intracellular aggregation29.
On the other hand, several studies have shown that Cys111 could be
a potential target for the development of compounds to stabilise
SOD1. Binding of small molecules to this residue does not only
reduce the chance of oxidative modification, but also promotes
dimer stability by tethering each monomer or providing additional
Fig. 3 The structures of A4V SOD1 with bound ligands. a Cartoon representation of A4V SOD1 dimer with ligands. The ligands (yellow sticks with
valences) bind each monomer (purple and blue) at Cys111, located at the dimer interface. Dark grey spheres represent Zn in the Zn binding sites and light
grey spheres represent Zn in the Cu binding site. Details of ligand binding of b A4V-ebselen, c A4V-compound 1, d A4V-compound 4 and e A4V-
compound 6. The Fo-Fc map contoured at 3σ (green) shows the electron density of the ligands. The 2Fo-Fc map contoured at 1σ (grey) shows the electron
density of Cys111 residues. f The superposed structures of A4V-ebselen (magenta) and A4V-compound 4 (cyan) monomers, depicting the binding pose of
each compound.
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interactions between two monomers11–13. Our study shows that
when ebselen and its analogues bind only to Cys111 of A4V SOD1,
they increase the thermal stability of the protein. The crystal
structures of ligand-bound A4V mutant and wild-type SOD113
agree with the thermal shift study that the compounds form a
covalent bond with the sulphur atom of Cys111 of each monomer
and the aromatic rings are in the position which promotes face-to-
face π–π stacking interaction. This hydrophobic interaction is ubi-
quitously present in biological macromolecules and important for
protein-protein or protein-nucleic acid recognition. The aromatic
ring of hydrophobic amino acids also contributes to protein folding
and maintaining secondary structure, providing approximately 1
kcal/mol of energy to protein stability31–34. The extended dimeric
contact by π–π stacking interaction in our crystallographic study
might strengthen the existing hydrogen and hydrophobic interac-
tions at the dimer interface, without changing interdimeric distance,
and thereby increasing A4V SOD1 thermal stability.
Our thermal shift assay shows the differences in the melting
temperature of the proteins upon binding to ligands. While the
unfolding of proteins may not always indicate the aggregation
process or the degree of dimer stability9,10, this method is feasible
for the screening of ligand-protein interactions35. The result of DSF
showed that lower molecular mass compounds (ebselen and com-
pounds 1–5) could increase thermal stability of WTC6S and A4VC6S
more than larger mass compounds (compounds 6–10). The smaller
compounds might fit in the dimeric groove better than the larger
compounds without disturbing the interaction at the dimer inter-
face and could form π–π stacking interaction as mentioned above.
Notably, compounds 3, 4 and 5, which are methylene-linked ana-
logues, greatly increased SOD1 melting temperatures. This result
can be understood because the methylene linker makes the
aromatic tail group more flexible, allowing the chlorobenzyl ring to
localise between N- and C-termini and interact with Ile151, which is
a residue critical for maintaining hydrogen bonding between two
monomers. Thus, the binding pose as demonstrated in A4V-
compound 4 structure might serve as a bridge, reinforcing the
interaction at the dimer interface.
Although increasing the number of aromatic rings of the small
molecules is one of the methods to make the ligand more
permeable to lipid bilayer of cell membranes, the increase in size
and hydrophobicity could reduce its solubility and affect the
binding affinity for the target protein32,36. The slight increases, or
even decreases, in the melting temperature of compounds 6–10 in
our study may be due to the steric restriction that prevents the
head group from gaining access to the binding site, or the com-
pounds in solution might adopt the binding pose that less favours
π-π stacking interactions. The structure of compounds 6 and 7
contains ebselen as a core with the addition of phenyl ring and
trifluoromethyl group resulting in relatively different properties
from ebselen, as demonstrated in Fig. 1, especially their size and
solubility. The decrease in Tm of the protein when binding to
compounds 6 and 7may be because the biphenyl trifluoromethyl-
containing compounds adopt a different binding pose or a dif-
ferent binding site from the crystal structure. The strong elec-
tronegativity of fluorine37 may also interfere with the bonding at
the dimer interface. In addition, the biphenyl tail group without
methylene bridge in compounds 6 and 7 may increase hydro-
phobicity of the compounds with less flexibility than compounds
8, 9 and 10. The position and the binding site in solution, toge-
ther with the strong electronegativity and rigidity, probably cause
repulsion across the dimer interface, resulting in a shift of the
monomer-dimer equilibrium toward monomer, which was
Fig. 4 Ligand-ligand and ligand-A4V SOD1 interactions. a A4V-ebselen, b A4V-compound 1, c A4V-compound 4 and d A4V-compound 6. The ligands
are represented as yellow ball and stick, and waters are represented as red dots. The selenium atom (orange) of the ligand binds covalently to the sulphur
atom (cyan) of Cys111. Hydrophobic interactions (pink dashed lines) are shown between the aromatic rings (π-π stacking) of the ligands bound at the dimer
interface, between the phenyl ring of the ebselen and Gly108-Asp109 amide bond (amide-π stacking) of the A4V-ebselen structure, and between the
chlorobenzyl group and Ile151 (σ-π interaction) of the A4V-compound 4 structure. An electrostatic anion-π interaction (orange dashed line) is shown
between the aromatic ring of compound 6 and the side chain of Asp109. Water-bridged hydrogen bonds (blue dashed lines) are found in A4V-ebselen and
A4V-compound 1 structures. An additional hydrogen bond (green dashed line) is also found between the nitrogen atom of the pyridine ring of compound 1
and Gly108 backbone amide.
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shown to have lower thermal stability38. However, our study
shows that the compounds could not only bind at Cys111, but
also Cys6 in solution which may be due to the hydrophobicity of
the compounds that could penetrate into the β-barrel structure.
We must remember that intracellular SOD1 is unlikely to
encounter the high concentration of ebselen derivatives used for
in vitro conjugation here, but this characteristic will be considered
for the development of the next generation of ebselen analogues.
To make the compounds more hydrophilic and less rigid,
incorporating hydrophilic saturated heterocycles together with
flexible linkers to ebselen would be interesting strategies for
developing small compounds that react with Cys111 and form
hydrogen bonds with the surrounding residues thereby increasing
the ligand-ligand and ligand-protein interactions while main-
taining the desirable CNS MPO score.
In spite of our best efforts, we could not obtain the crystal
structure of A4V SOD1 with ebsulphur bound. The DSF result
demonstrates that ebsulphur and its analogues also promote ther-
mal stability of WTC6S and A4VC6S, but to a much lesser extent
than ebselen derivatives, and AMS modification of free cysteines
shows the mobility shift of the protein with ebsulphur which may
be due to a stronger reactivity of selenium than sulphur39. This is
consistent with our previous study, showing the smaller increase in
dimer affinity when SOD1 mutants are bound to ebsulphur com-
pared to ebselen13. Therefore, future development of SOD1-targeted
compounds should focus mainly on selenium-containing or possi-
bly tellurium-containing ebselen derivatives.
In conclusion, our study has developed the DSF assay using C6S
background SOD1, which can provide medium-throughput eva-
luation of candidate lead compounds prior to co-crystallography
and cellular evaluation. We present the promising capability of
ebselen and its derivatives with molecular weight below 400Da in
promoting the thermal stability of A4V SOD1 when binding to
Cys111 only. The binding site in A4V SOD1 of ebselen-based
compounds has been validated by crystallographic study indicating
all lead compounds form a covalent bond of Se–S to the side chain
of Cys111. Small compact selenium compounds with flexible link-
age, e.g., compounds 3–5, are more potent candidates than sulphur-
containing compounds in stabilising the SOD1 dimer. Although the
crystal structures show the binding of compounds to Cys111 in the
position which could facilitate π–π stacking interaction, it is possible
that the large ligands have more rotational freedom in solution,
which may disrupt the dimeric interaction and should be con-
sidered when designing new ligands. We note that none of the
previous attempts for chemical intervention with A4V have yielded
compounds in crystallographic structure of A4V9,13. This has
hampered structure-based lead optimisation due to paucity of basic
knowledge on the binding region and associated interactions critical
for understanding binding space and setting a strategy for
knowledge-based lead optimisation. However, to become a potential
medication, our ebselen derivative series should be improved
probably by combining interactions seen with different compounds
while increasing solubility and specificity to eliminate the possibility
of binding to Cys6. Therefore, this study provides a platform for
using the ebselen analogue template for structure-based drug
development for ALS therapeutics.
Methods
Synthesis of ebselen-based and ebsulphur-based compounds. Details for the
synthesis of ebselen and ebsulphur analogues are included in the supplementary
information.
Recombinant SOD1 production. The mutant A4V SOD1 was generated by site-
directed mutagenesis as previously described13. The mutant wild-typeC6S (WTC6S)
and A4VC6S SOD1s were also produced by site directed mutagenesis (Genscript).
The pET303C plasmids containing wild-type, A4V, WTC6S and A4VC6S human
SOD1 genes were transformed into E. coli BL21 (DE3). Protein expression was
induced with 0.4 mM Isopropyl β-d-1-thiogalactopyranoside (IPTG) supplemented
with 0.3 mM ZnCl2 and incubated at 18 °C overnight. Proteins were purified as
previously described40. Briefly, proteins in 20 mM Tris-HCl pH 8.0 were purified
using ion-exchange chromatography on diethylaminoethanol sepharose and eluted
in a stepwise gradient concentration of NaCl. Proteins in the low NaCl con-
centration (5–100 mM) were pooled and subjected to size-exclusion chromato-
graphy on a Superdex 200 16/600 column in Tris-buffered saline (TBS) pH 7.4. The
purified proteins were snap-frozen in liquid nitrogen and stored at −20 °C. The
concentration of all SOD1 proteins was measured by ultraviolet spectrometry at
280 nm using a monomeric molar extinction of 5500M−1cm−1.
Crystallisation. Ebselen and compound 6 were dissolved in DMSO for 150 mM
stock solution which were then added to 3.9 mg/mL (250 μM) of A4V SOD1 to a
final concentration of 1 mM. The mixtures were incubated at room temperature for
2 h before crystallisation. The crystals were grown using the hanging drop method
by mixing 2 μL of the protein solution and 2 μL of reservoir solution containing
100 mM Tris-HCl pH 7.4–8.0, 2.4–2.6 M ammonium sulphate, 150 mM NaCl. The
A4V SOD1 crystals in C2 space group were grown from the mixture of the protein
and ebselen in the same conditions; however, no electron density of the compound
was observed in the structure. Compound 1 and compound 4 were prepared from
the same concentration of stock solution before adding to 5 mg/mL (300 μM) of
A4V SOD1 to a final concentration of 500 μM. The mixtures were pre-incubated at
4 °C overnight before crystallisation. The crystals were grown using the hanging
drop method by mixing 1 μL of the protein solution and 1 μL of reservoir solution
Fig. 5 Superposition of A4V SOD1 C2 structures. All dimers in the
asymmetric unit (ASU) of each structure were overlaid onto one dimer of the
A4V SOD1 structure without ligands. The average RMSD of three dimers in
the ASU of the A4V SOD1 structure is 0.19 Å. The expanded box shows the
detail of loop VI which is more opened in the compound-bound A4V
SOD1 structures. The table shows the maximum and the minimum of RMSD
of each ligand-conjugated structure compared to the structure without ligands.
Table 3 The RMSD of the ligand-conjugated A4V
SOD1 structures compared to the A4V SOD1 in C2 form
structure without ligands.
Structures No. of dimers in the ASU RMSD (Å)
A4V-ebselen 3 0.24–0.33
A4V-cpd 1 3 0.21–0.32
A4V-cpd 4 6 0.19–0.60
A4V-cpd 6 3 0.30–0.40
The figures are ranges of the maximum and the minimum of the RMSD of each structure.
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as mentioned above. All protein crystals were grown at 20 °C. The crystals were in
mature size after 3–5 days and then soaked in 20% glycerol in reservoir solution
before being snap-frozen in liquid nitrogen.
Data collection and structural determination. For A4V-ebselen crystal, data were
collected at Barkla X-ray laboratory, University of Liverpool with 1.54 Å wave-
length using Rigaku FR-E+ Super-Bright rotating anode generator with an EIGER
R 4M detector to 2.2 Å resolution at 100 K, followed by integration using automar
software41 and scaling using Aimless42. Other data were collected using the I04-1
beamline at the Diamond Light Source (Harwell, UK) at 100 K with x-rays of
wavelength 0.92 Å, integrated using DIALS43 or iMOSFLM44 and scaled using
Aimless42. All structures were solved by molecular replacement using MOLREP45
software as a part of CCP4 program suite46, and A4V SOD1 structure (1UXM;
chain A and B) was used as a starting model. Restrained refinement in
Refmac547,48 was iterated with model building in COOT49. In the final stages of
refinement, TLS refinement was used to refine A4V-ebselen structure, and
hydrogen atoms were added in riding position to all structures. The models of
ebselen and ebselen-based compounds were produced in JLigand50. The structures
were validated using MolProbity50 before being deposited in the Protein Data Bank
(PDB codes 6SPA, 6SPH, 6SPI, 6SPJ and 6SPK).
Differential scanning fluorimetry (DSF). DSF was carried out using a StepO-
nePlus Real-Time PCR machine (Life Technologies). Proteins at 40 μM were pre-
incubated with 100 μM of ebselen and ebselen analogues prepared from 150 mM
stock solution at 4 °C overnight. The final concentration of DMSO in the mixture
was 1.25% (v/v). Prior to DSF assay, the mixture was dialysed against TBS at 4 °C
for 3 h to remove excess compounds. SYPRO Orange dye (Life Technologies) dye
at 10× concentration was used as a probe. Fluorescent intensities were monitored
from 25 °C to 95 °C at a ramp rate of 0.3 °C/min. The analysis of melting tem-
perature (Tm) was based on the Boltzmann equation and calculated using the
TmToolTM software (Life Technologies).
Free-thiol assay. A4VC6S SOD1 was pre-incubated with ebselen and ebsulphur as
previously stated. After removal of excess compounds, the samples were blocked
with 100-fold excess of 4-acetamido-4′-maleimidylstilbene-2,2′-disulfonic acid
(AMS) for 2 h at 37 °C before being separated by denaturing 15% SDS-PAGE.
Statistics and reproducibility. In DSF assay, data were taken from 3 independent
experiments with 4–6 replicates per experiment. Each protein was from a single
batch of purification. In crystallographic study, high multiplicity could be obtained
from data collection of a single crystal.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Crystal structures of A4V SOD1 with compounds are deposited in the Protein Data Bank
under accession number 6SPA, 6SPH, 6SPI, 6SPJ, and 6SPK. Other relevant data are
available upon request from the corresponding author.
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